Diabetes drug study for lung cancer patients
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at whether a common diabetes medication can help people with lung cancer and type 2 diabetes live longer. If you have both conditions and are receiving standard cancer treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer and are receiving standard treatment for it.
- You have type 2 diabetes.
- You are generally able to care for yourself (score 0-2 on a standard health scale).
- You do not have severe liver, kidney, or heart problems.
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety of dapagliflozin (a diabetes drug) taken before surgery for stage IA lung adenocarcinoma. It may help understand if this drug can slow tumor growth while waiting for surgery.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.